Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Non-Current Assets for 10 consecutive years, with $59.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 59.67% to $59.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.7 million through Dec 2025, up 59.67% year-over-year, with the annual reading at $59.7 million for FY2025, 59.67% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $59.7 million at Akebia Therapeutics, up from $40.5 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $69.6 million in Q3 2021, with the low at $3.3 million in Q2 2023.
  • Average Other Non-Current Assets over 5 years is $31.7 million, with a median of $36.2 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets crashed 90.42% in 2023, then soared 602.59% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $50.4 million in 2021, then plummeted by 89.35% to $5.4 million in 2022, then skyrocketed by 131.25% to $12.4 million in 2023, then skyrocketed by 200.87% to $37.4 million in 2024, then surged by 59.67% to $59.7 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $59.7 million, $40.5 million, and $44.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.